OnKure Therapeutics, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 377.3K | $1.56M | 0.00% | Added+52.5% | 2026-03-31 |
| TwoSigma | quant | 24.3K | $100.44K | 0.00% | Added+114.3% | 2026-03-31 |
| StateStreet | passive | 13.5K | $55.73K | 0.00% | New | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-05 | -0.74 | -1.11 | -49.49% |
| 2026-03-12 | -1.15 | -0.99 | +14.06% |
| 2025-11-06 | -1.20 | -1.09 | +9.02% |
| 2025-08-12 | -1.25 | -1.14 | +8.65% |
| 2025-05-05 | -1.38 | -1.19 | +13.77% |
| 2025-03-10 | -0.87 | -1.37 | -57.47% |
| 2024-11-07 | -0.90 | -0.86 | +4.44% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| OKUR | -11.21% | +42.37% | +44.83% | +66.01% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -14.17% | +47.01% | +48.27% | +53.32% |